U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C19H28N2O4
Molecular Weight 348.4366
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROXATIDINE ACETATE

SMILES

CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

InChI

InChIKey=SMTZFNFIKUPEJC-UHFFFAOYSA-N
InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.drugsupdate.com/generic/view/456/Roxatidine | https://www.ncbi.nlm.nih.gov/pubmed/1717223 | https://www.ncbi.nlm.nih.gov/pubmed/20718616

Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: Small amounts of roxatidine were detectable in the CSF, the CSF to plasma ratio ranging from 0 to 0.89.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Primary
Approved
8583
ROXATIDINE

Approved Use

Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
157.5 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
329 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
628.5 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
353.6 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=82
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
530.2 ng/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=83
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1353.2 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2424.5 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5275.2 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2053.6 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=82
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
3587.5 ng × h/mL
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=83
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.57 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.03 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.01 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=7 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=70
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.62 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=82
37.5 mg single, oral
dose: 37.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
4.17 h
OTHER GOV'T
https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_A100_2.pdf#page=8 | https://www.pmda.go.jp/drugs/2011/P201100027/470007000_16100AMZ03538000_K100_2.pdf#page=83
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROXATIDINE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
85%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2905248/
ROXATIDINE unknown
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
Other AEs: Skin rash...
Other AEs:
Skin rash (10%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash (grade 3, 0.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
AEs

AEs

AESignificanceDosePopulation
Skin rash 10%
600 mg single, oral
Highest studied dose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: FASTED
Sources:
https://pubmed.ncbi.nlm.nih.gov/2906457/
Rash grade 3, 0.5%
Disc. AE
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/2905241/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP
303
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
303
 no
PubMed

PubMed

TitleDatePubMed
Histamine H2-receptor antagonistic action of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)acetoxyacetamide hydrochloride (TZU-0460).
1985
Patents

Patents

JP2011157298
4
JPH06271467A
4

Sample Use Guides

In Vivo Use Guide
Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime. Gastro-oesophageal reflux disease: 75 mg bid or 150 mg at bedtime for 6-8 weeks. Gastritis: 75 mg once daily in the evening. Zollinger-Ellison syndrome: 75 mg bid. Premedication before anaesthesia: 75 mg in the evening on the day before surgery and repeated 2 hours before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery. Intravenous Upper gastrointestinal haemorrhage: 75 mg bid via slow injection or infusion.
Route of Administration: Other
In Vitro Use Guide
6.25-25 uM Roxatidine suppressed the PMACI-induced production of pro-inflammatory cytokines in HMC-1
Name Type Language
ACETAMIDE, 2-(ACETYLOXY)-N-(3-(3-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL-
Preferred Name English
ROXATIDINE ACETATE
MI   VANDF   WHO-DD  
Common Name English
Roxatidine acetate [WHO-DD]
Common Name English
ROXATIDINE ACETATE [VANDF]
Common Name English
PIFATIDINE
Common Name English
ROXATIDINE ACETATE [MI]
Common Name English
Code System Code Type Description
RXCUI
35803
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY RxNorm
EVMPD
SUB04277MIG
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID2048325
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
CAS
78628-28-1
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
MERCK INDEX
m9677
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY Merck Index
PUBCHEM
5105
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
SMS_ID
100000084943
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
DRUG CENTRAL
2408
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
FDA UNII
ZUP3LSD0DO
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL46102
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
MESH
C053742
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
DRUG BANK
DB08806
Created by admin on Mon Mar 31 19:30:16 GMT 2025 , Edited by admin on Mon Mar 31 19:30:16 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of ROXATIDINE
SUBSTANCE RECORD
Structure of ROXATIDINE ACETATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966